S
Steve Ryder
Researcher at York University
Publications - 8
Citations - 2188
Steve Ryder is an academic researcher from York University. The author has contributed to research in topics: Internal medicine & Population. The author has an hindex of 5, co-authored 5 publications receiving 1641 citations.
Papers
More filters
Journal ArticleDOI
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Penny Whiting,Penny Whiting,Robert Wolff,Sohan Deshpande,Marcello Di Nisio,Steven Duffy,Adrian V. Hernandez,Adrian V. Hernandez,J. Christiaan Keurentjes,Shona H. Lang,Kate Misso,Steve Ryder,Simone Schmidlkofer,Marie Westwood,Jos Kleijnen +14 more
TL;DR: There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.
Journal ArticleDOI
The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy : an evidence review
Steve Ryder,Regina M. Leadley,Nigel Armstrong,Marie Westwood,S. de Kock,Thomas Butt,Mohit Jain,Jos Kleijnen +7 more
TL;DR: This first systematic review of treatment, progression, severity and quality of life in Duchenne Muscular Dystrophy provides the most recent description of the burden, epidemiology, illness costs and treatment patterns in DMD.
Journal ArticleDOI
A systematic review of the international prevalence of BRCA mutation in breast cancer
TL;DR: Poor reporting of gBRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer.
Journal ArticleDOI
Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
Penny Whiting,Maiwenn Al,Laura Burgers,Marie Westwood,Steve Ryder,Martine Hoogendoorn,Nigel Armstrong,A Allen,Hans Severens,Jos Kleijnen +9 more
TL;DR: The available evidence suggests that ivacaftor is a clinically effective treatment for patients with CF and the G551D mutation; the high cost of ivACaftor may prove an obstacle in the uptake of this treatment.
Journal ArticleDOI
SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
R Riemsma,Maiwenn Al,I. Corro Ramos,Sohan Deshpande,Nigel Armstrong,Y-C Lee,Steve Ryder,Caro Noake,Marieke Krol,Mark Oppe,Jos Kleijnen,Hans Severens +11 more
TL;DR: A systematic review was conducted to summarise the evidence on the clinical effectiveness of Se HCAT for the assessment of BAM and the measurement of bile acid pool loss and found three studies assessing the relationship between the SeHCAT test and response to treatment with cholestyramine.